Greg Harrison
Stock Analyst at B of A Securities
(4.51)
# 259
Out of 5,242 analysts
101
Total ratings
56.79%
Success rate
22.04%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Buy | $44 → $41 | $28.50 | +43.86% | 10 | Apr 21, 2026 | |
| UTHR United Therapeutics | Maintains: Neutral | $569 → $626 | $563.93 | +11.01% | 6 | Mar 31, 2026 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $46 → $51 | $28.43 | +79.39% | 3 | Mar 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $495 → $558 | $430.44 | +29.63% | 8 | Feb 13, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $36 → $30 | $12.26 | +144.70% | 3 | Oct 27, 2025 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $43.49 | -28.72% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $8.03 | +149.07% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $68.22 | -16.45% | 7 | Aug 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $298.48 | +50.76% | 6 | Aug 1, 2025 | |
| GOSS Gossamer Bio | Initiates: Sector Outperform | $11 | $0.2153 | +5,009.15% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $32 → $35 | $6.82 | +413.20% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $34.62 | +58.87% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $51 → $19 | $2.97 | +539.73% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $61.77 | -40.10% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $10.98 | +136.79% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.26 | +19.05% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $27.11 | +47.55% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $67.03 | +11.89% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $12.50 | +44.00% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $30.30 | -60.39% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $2.60 | +476.92% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $12.38 | -75.77% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.98 | +7,042.86% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $17.97 | +200.50% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $69.49 | +29.52% | 5 | Mar 14, 2022 |
Agios Pharmaceuticals
Apr 21, 2026
Maintains: Buy
Price Target: $44 → $41
Current: $28.50
Upside: +43.86%
United Therapeutics
Mar 31, 2026
Maintains: Neutral
Price Target: $569 → $626
Current: $563.93
Upside: +11.01%
Mineralys Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $46 → $51
Current: $28.43
Upside: +79.39%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Sector Perform
Price Target: $495 → $558
Current: $430.44
Upside: +29.63%
Intellia Therapeutics
Oct 27, 2025
Maintains: Buy
Price Target: $36 → $30
Current: $12.26
Upside: +144.70%
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $43.49
Upside: -28.72%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $8.03
Upside: +149.07%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $68.22
Upside: -16.45%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $298.48
Upside: +50.76%
Gossamer Bio
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $0.2153
Upside: +5,009.15%
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $6.82
Upside: +413.20%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $34.62
Upside: +58.87%
May 28, 2025
Maintains: Sector Outperform
Price Target: $51 → $19
Current: $2.97
Upside: +539.73%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $61.77
Upside: -40.10%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $10.98
Upside: +136.79%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.26
Upside: +19.05%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $27.11
Upside: +47.55%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $67.03
Upside: +11.89%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $12.50
Upside: +44.00%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $30.30
Upside: -60.39%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $2.60
Upside: +476.92%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $12.38
Upside: -75.77%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $0.98
Upside: +7,042.86%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $17.97
Upside: +200.50%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $69.49
Upside: +29.52%